Arxada invests CHF20m in Czech industrial biotech plant

Upgrades at Kouřim facility will benefit Arxada’s Contract Development Manufacturing Organization business

Speciality chemicals business Arxada has announced a CHF20m investment in its industrial biotechnological plant in Kouřim, Czech Republic.

The facility serves Arxada’s CDMO, or Contract Development Manufacturing Organization – part of Arxada’s Specialty Products Solutions business.

The Bain Capital and Cinven-owned company is divided into two segments: Microbial Control Solutions and Specialty Products Solutions, which also includes performance intermediates and chemicals, and composite materials.

Lukas von Hippel, VP of the CDMO Business Line at Arxada, commented: “Our site in Kouřim is an integral part of our future strategy. Following the implementation of our new strategy in May 2020, we have seen more customers seeking our support in their new projects.

“Our business development team together with our process development team in Kouřim can speed up development and shorten time to market by over a year in some cases.”

“We are seeing growing demand for CDMO projects in biotech,” added Zdena Cermakova, Kouřim Site Head, Arxada.

Companies